Chlamydomonas reinhardtii: A Factory of Nutraceutical and Food Supplements for Human Health

Chlamydomonas reinhardtii (C. reinhardtii) is one of the most well-studied microalgae organisms that revealed important information for the photosynthetic and metabolic processes of plants and eukaryotes. Numerous extensive studies have also underpinned its great potential as a biochemical factory, capable of producing various highly desired molecules with a direct impact on human health and longevity. Polysaccharides, lipids, functional proteins, pigments, hormones, vaccines, and antibodies are among the valuable biomolecules that are produced spontaneously or under well-defined conditions by C. reinhardtii and can be directly linked to human nutrition and diet. The aim of this review is to highlight the recent advances in the field focusing on the most relevant applications related to the production of important biomolecules for human health that are also linked with human nutrition and diet. The limitations and challenges are critically discussed along with the potential future applications of C. reinhardtii biomass and processed products in the field of nutraceuticals and food supplements. The increasing need for high-value and low-cost biomolecules produced in an environmentally and economy sustainable manner also underline the important role of C. reinhardtii.

Hypolipidemic effects of fucoidan fractions from Saccharina sculpera (Laminariales, Phaeophyceae)

Fucoidan is a kind of brown algae-derived macromolecule suggested to have hypolipidemic activity. Saccharina sculpera has attracted interest because it is rich in fucoidan. The monosaccharide composition and structural characteristics of isolated fractions (F1, F2 and F3) were determined using high-performance liquid chromatography (HPLC), Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance spectroscopy (NMR). The hypolipidemic effects of fucoidan fractions from Saccharina sculpera cultured in northern China were clarified by measuring cholesterol levels, antioxidative indicators and hepatic gene mRNA expression using an established hyperlipidemic Wistar rat model. The results showed that F1 is an acetylated galactofucan and that F2 consists of fucose, galactose, mannose and glucuronic acid. F3 is an acetylated galactofucan with high fucose. Fucoidan fractions from Saccharina sculpera could effectively reduce the level of lipids in serum by reducing the TG, TC, and LDL-C levels and increasing HDL-C levels and could effectively prevent lipid accumulation in the liver. The findings obtained from hepatic gene expression showed that fucoidan could inhibit cholesterol synthesis via downregulation of HMG-CoA-R and upregulation of LCAT, slow the synthesis of fatty acids via downregulation of SREBP-1c, and promote β-oxidation of fatty acids via upregulation of PPARα, PPARγ and LPL. These results demonstrated that the hypolipidemic activity of fucoidan was related to the inhibition of cholesterol synthesis and reverse transport, the regulation of fatty acid synthesis, and acceleration of mitochondrial β-oxidation.

Deciphering the anti-Parkinson’s activity of sulphated polysaccharides from Chlamydomonas reinhardtii on the α-Synuclein mutants A30P, A53T, E46K, E57K and E35K

Parkinsonism-linked mutations in alanine and glutamic acid residues of the pre-synaptic protein α-Synuclein (α-Syn) affect specific tertiary interactions essential for stability of the native state and make it prone to more aggregation. Many of the currently available drugs used for the treatment of Parkinson’s disease (PD) are not very effective and are associated with multiple side effects. Recently, marine algae have been reported to have sulphated polysaccharides which offers multiple pharmaceutical properties. With this background, we have isolated sulphated polysaccharides from Chlamydomonas reinhardtii (Cr-SPs) and investigated their effects on inhibition of fibrillation/aggregation of α-Syn mutants through a combination of spectroscopic and microscopic techniques. The kinetics of α-Syn fibrillation establishes that Cr-SPs are very effective in inhibiting fibrillation of α-Syn mutants. The morphological changes associated with the fibrillation/aggregation process have been monitored by transmission electron microscopy. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis gel image suggests that Cr-SPs increase the amount of soluble protein after completion of the fibrillation/aggregation process. The circular dichroism results showed that Cr-SPs efficiently delay the conversion of native protein into β-sheet-rich structures. Thus, the current work has considerable therapeutic implications towards deciphering the potential of Cr-SPs to act against PD and other protein aggregation-related disorders.